Introduction
Multiple myeloma is a B-lymphocyte malignancy characterized by a low-grade proliferation of monoclonal plasma cells in the bone marrow. A majority of patients develop osteolytic bone lesions that cause substantial morbidity. Although several pharmacological substances are able to inhibit myeloma cell growth in vitro, only a few cytokines inhibit myeloma cell growth. Among them are activin A (Nishihara et al., 1993) , bone morphogenetic protein (BMP)-2 (Kawamura et al., 2000) , BMP-4 (Hjertner et al., 2001) , TNF-related apoptosis-inducing ligand (TRAIL) (Gazitt, 1999) , Fas ligand (Shima et al., 1995) and interferon gamma (Jernberg-Wiklund et al., 1991) .
The transforming growth factor (TGF)-b superfamily members include TGF-bs, activins/inhibins and BMPs. BMPs were originally identified as molecules capable of inducing bone and cartilage formation (Urist, 1965) . The bone-inducing effect is caused by osteoblast differentiation of cells derived from mesenchymal stem cells, and is thought to play a role in adult bone remodeling and in fracture repair. However, more recent knowledge shows that BMPs regulate a broad spectrum of biological responses like proliferation, differentiation and apoptosis in a wide variety of cell types, including hematopoietic cells (Bhatia et al., 1999) .
Based on amino-acid homology, the BMPs can be further subdivided into different classes, with BMP-2 and -4 in one category, and BMP-5, -6, -7 and -8 in a second category. To initiate their cellular response, TGF-b family members simultaneously bind to two different membrane-bound receptors with intrinsic serine/threonine kinase activity: type I receptors and type II receptors. The various members of the TGF-b superfamily make use of different type I and type II receptors. To date, seven type I receptors have been identified, denoted as activin-like kinase (Alk) 1-7 (ten Dijke et al., 1994a; Tsuchida et al., 1996) . Activins bind to Alk-2 and -4, whereas TGF-b binds to Alk-1 and -5. BMP-6 and -7 bind to Alk-2 (also known as activin receptor I) (Ebisawa et al., 1999) , whereas BMP-2 and -4 predominantly bind to Alk-3 and -6 (also known as BMP receptor IA and IB, respectively) (ten Dijke et al., 1994b) . To our knowledge, the type I receptor for BMP-5 has not been determined. All BMPs utilize the same type II receptor (BMPR II). Following ligand binding to the type I receptor, the type II receptor crossphosphorylates the type I receptor. This phosphorylation activates the type I receptor kinase domain and initiates downstream signalling, mainly through the phosphorylation and activation of a group of transcription factors known as Smads. TGFb utilizes Smad-2 and -3, while BMPs signal via Smad-1, -5 and -8. These Smad proteins (also named receptor-Smads or R-Smads) combine with Smad-4 (alias co-Smad) in the cytoplasm before they enter the nucleus and initiate transcription.
BMPs may be involved in protection against several types of cancer. BMP-7 induces cell cycle arrest of anaplastic thyroid carcinomas (Franzen and Heldin, 2001) , and overexpression of BMP-6 in murine epidermis supresses skin tumor formation (Wach et al., 2001) . In prostate cancer, loss of BMP receptors is an unfavorable prognostic factor (Kim et al., 2000) . Deletions of downstream signalling molecules are linked to acute myeloid leukemia (Smad-5) (Zavadil et al., 1997) and to carcinoma of the pancreas (Smad-4) (Hahn et al., 1996) . Retinoic acid, a substance sometimes used as an antineoplastic agent, is able to induce cell death through BMP signalling (Rodriguez-Leon et al., 1999; Hallahan et al., 2003) .
The TGF-b receptor is downregulated as B lymphocytes mature into plasma cells (Tarte et al., 2003) . Provided this is also the case for myeloma cells, it may explain why the tumor-suppressive effect of TGF-b is generally weak in multiple myeloma (Urashima et al., 1996) . As shown by our group earlier, BMP-4 inhibits proliferation and induces apoptosis in some myeloma cell lines and in freshly harvested myeloma cells (Hjertner et al., 2001) . However, several cell lines, as well as occasional primary myeloma cell samples, are resistant to BMP-4 treatment. The fact that BMP-6 and -7 signal through different type I receptors than BMP-2 and -4 lead us to examine the expression pattern of BMP receptors on human myeloma cell lines. In addition, we wanted to examine whether BMP-5, -6 and -7 influenced myeloma cells similarly or differently from BMP-4.
Results

There was variability in BMP receptor expression in five human myeloma cell lines
We determined the expression of the four BMP receptors Alk-2, -3, -6 and BMPR II on the cell lines ANBL-6, IH-1, OH-2, RPMI-8226 and INA-6 by RT-PCR. The results are shown in Figure 1 . Alk-2 (type I receptor for BMP-6 and -7) and BMPR-II were expressed by all the five cell lines, and in INA-6 and RPMI-8226 only these two receptors were found. IH-1 cells expressed mRNA for all the four receptors, and were the only cells that expressed Alk-6.
BMP-4, -5, -6 and -7 inhibited proliferation of human myeloma cell lines
To examine the proliferative response of the cell lines ANBL-6, IH-1, INA-6, OH-2 and RPMI-8226, we treated the cells for 3 days with various concentrations of BMP-4, -5, -6 and -7, and measured 3 H-thymidine incorporation. An optimal dose (see the legend to Figure 2 ) of interleukin-6 (IL-6) was added to the IL-6-dependent cell lines ANBL-6, IH-1, INA-6 and OH-2. BMP-6 and -7 reduced proliferation in a dose-dependent manner in all the five human myeloma cell lines (Figure 2 ), which was expected because all cell lines apparently express Alk-2. Conversely, BMP-4 reduced proliferation only in three cell lines (ANBL-6, IH-1 and OH-2). The two cell lines with no detectable Alk-3 and Alk-6 transcripts (INA-6 and RPMI-8226) did not respond to BMP-4. The same response pattern as for BMP-4 was found for BMP-2, another member of the BMP family, using Alk-3 or Alk-6 as its type I BMP receptor (data not shown).
BMP-5 reduced proliferation in the cell lines IH-1, OH-2 and RPMI-8226, but had little or no effect in the ANBL-6 and INA-6 cell lines. In contrast to our previous results with BMP-4 on IL-6-independent cell lines (Hjertner et al., 2001) , there was a minor effect of BMP-5, -6 and -7 on RPMI-8226 cells. We were, however, not able to detect any decrease in proliferation in the two IL-6-independent cell lines JJN-3 and U-266 (data not shown). The 50% effective dose (ED 50 ) values from our experiments agree well with ED 50 values reported in other biological BMP-assays (Beck et al., 2001; Franzen and Heldin, 2001) .
Next, we looked for synergistic effects by combining different BMPs. We tried both BMPs using the same type I receptor and BMPs using different type I receptors. Combining different BMPs gave additive effects on the inhibition of myeloma cell growth, regardless of which type I receptor the BMPs used. In Figure 3 , this is exemplified by combining BMP-4 and -7 in IH-1 cells, and by combining BMP-6 and -7 in INA-6 cells. Other combinations gave similar additive effects, Figure 1 Expression pattern of mRNA for different BMP receptors in the myeloma cell lines. The expression patterns of the type I BMP receptors Alk-2 (receptor for BMP-6 and -7), -3 and -6 (receptors for BMP-2 and -4) as well as BMP receptor type II in the myeloma cell lines ANBL-6, IH-1, INA-6, OH-2 and RPMI-8226 were determined by RT-PCR. Actin was included as a loading control. RNA from each cell line was analysed without prior generation of cDNA (control -RT), and a PCR reaction for each set of primers was run without cDNA (control -cDNA) BMP-5, -6 and -7 inhibit myeloma cell growth T Baade Ro et al provided that the given BMP had an effect by its own in the cell line studied. When two different BMPs were combined, a lower dose of each BMP was required to achieve an inhibitory response. However, synergistic effects of combinations of two or more BMPs were not seen.
BMP-5, -6 and -7 induced apoptosis in myeloma cell lines and primary myeloma cells ANBL-6, IH-1, INA-6, OH-2 and RPMI-8226 cells were cultured for 2 days with or without BMP-5, -6 or -7. IL-6 was added to the IL-6-dependent cell lines. Cell viability was determined by annexin V-FITC/propidium iodide (PI) flow cytometry. The results are shown in Figure 4 . BMP-6 and -7 reduced cell viability in all cell lines examined, with the exception of ANBL-6 cells. In INA-6 and RPMI-8226 cells, BMP-5 had no effect on cell viability. This result agrees well with the result from We also cultured primary myeloma cells isolated from bone marrow specimens for a 2-day period in the presence or absence of BMP-4 (20 ng/ml), -5 (1000 ng/ml), -6 or -7 (300 ng/ml). These cells were not stimulated with IL-6. Viability was determined by annexin V-FITC/PI flow cytometry. The results are listed in Table 1 . In six out of nine patient samples, the cell viability was reduced significantly in response to BMP-6 (range 25-65%). Significant reduction in viability as a response to BMP-4, -5 and -7 treatment was found in four out of six, seven out of seven and five out of seven samples, respectively.
Soluble Alk-3 and -6 fully neutralized BMP-4-induced growth repression
To check the specificity of the BMP-receptor interactions in our cell lines, we added an excess of soluble Alk-3-Fc or -6-Fc in the presence of various BMPs. The results for the IH-1 cell line are shown in Figure 5 , and similar results were obtained in the OH-2 and INA-6 cell lines (data not shown). The soluble receptors and BMPs were preincubated for 30 min at 371C before cell seeding. Alk-3-Fc at five times higher concentration than the BMP concentrations fully neutralized BMP-4-induced growth inhibition and partially neutralized BMP-5-induced growth inhibition, but did not influence BMP-6 or -7-induced effects. There was a lower affinity for Alk-6-Fc: a 30-fold higher concentration than the BMP concentrations was needed to neutralize BMP-4-induced effects fully. At this concentration, there was a 20-60% inhibition of BMP-5, -6 or -7-induced growth repression as well. These results strongly suggest that BMP-4 binds to Alk-3 or -6 in our cell lines, whereas BMP-6 or -7 function via binding to another BMP receptor, for example, Alk-2.
Lack of Alk-3 and -6 receptor expression by RT-PCR corresponded to an inability by BMP-4 and -5 to phosphorylate the downstream signalling molecules Smad-1, -5 and -8
Following ligand-receptor binding and receptor di-or trimerization, kinase domains within the intracellular part of the receptors phosphorylate downstream signalling molecules like Smad-1, -5 and -8. To examine whether BMP-4 or -5 was able to induce Smad phosphorylation in INA-6 and RPMI-8226 cells, we Figure 6 , BMP-6 and -7 induced Smad phosphorylation in all of the cell lines examined, whereas BMP-4 and -5 did not induce Smad phosphorylation in the two cell lines missing Alk-3 and -6 mRNA transcripts.
BMP antagonist noggin abolished BMP-4 effects, but did not influence responses to In vivo, biological responses to BMPs are potentially counteracted by several BMP antagonists, including follistatin and noggin. To examine if follistatin or noggin was capable of rescuing myeloma cells from BMP-induced growth inhibition, IH-1 and OH-2 cells were treated for 3 days with IL-6 and BMP-4 (50 ng/ml), BMP-5 (300 ng/ml), BMP-6 or BMP-7 (50 ng/ml), with or without the BMP antagonists. The BMP antagonists were given in six times higher molar concentrations than the respective BMP. Cell proliferation was measured by 3 H-thymidine incorporation. As illustrated in Figure 7 for the IH-1 cell line, noggin antagonized the BMP-4 effect completely and the BMP-5 effect partially. IH-1 cell responses to BMP-6 or -7 were not significantly influenced by noggin. Follistatin antagonized BMP-5-induced effects partially. Activin A (50 ng/ml), a member of the TGFb superfamily, was included as a positive control for follistatin. Similar results were obtained in the OH-2 cell line, as well as in cell viability experiments, using annexin V-FITC/PI flow cytometry (data not shown). Alk-3-Fc (0.5 mg/ml, or 2.5 mg/ml with BMP-5) or Alk-6-Fc (3 mg/ml, or 15 mg/ml with BMP-5) with BMP-4 (100 ng/ml), BMP-5 (500 ng/ml), BMP-6 (100 ng/ml) or BMP-7 (100 ng/ml) were added to IH-1 cells in the presence of IL-6 (0.1 ng/ml) for 72 h. DNA synthesis was measured by 3 H-thymidine incorporation. Data shown are representative of three different experiments, and error bars represent 71 s.d. of triplicate measurements Figure 6 Detection of phospho-Smad1/5/8 in human myeloma cell lines following stimulation by BMPs. The cell lines ANBL-6, IH-1, INA-6, OH-2 and RPMI-8226 were treated with BMP-4 (50 ng/ml), BMP-5 (1500 ng/ml), BMP-6 (300 ng/ml) or BMP-7 (300 ng/ml) for 4 h, and phospho-Smad1/5/8 was detected by Western blotting. BMP-6 and -7 induced phosphorylation in all cell lines examined, whereas BMP-4 and -5 only phosphorylated in cells which had Alk-3 expressed by RT-PCR. The membranes were stripped and reprobed for Smad5, as shown for the OH-2 cell line in the lower panel BMP-5, -6 and -7 inhibit myeloma cell growth T Baade Ro et al
Discussion
This study adds BMP-5, -6 and -7 to the list of cytokines that are able to inhibit myeloma cell growth. Importantly, BMP-5, -6 and -7 inhibited proliferation and induced apoptosis also in BMP-2-and -4-resistant cell lines and in primary myeloma cells. We show that BMP-5, -6 and -7 inhibited proliferation and induced apoptosis in four IL-6-dependent myeloma cell lines, as well as in one IL-6-independent cell line. Thus, the lack of responses in some cell lines towards BMP-4 may be due to lack of expression of the appropriate type I BMP receptor, and not due to a general resistance to Smad-induced apoptosis. Furthermore, a clear proapoptotic response to BMPs in the majority of primary myeloma cell samples indicates that this is not merely a phenomenon seen in cell lines. Signalling by BMP involves two types of transmembrane serine/threonine kinases, termed type I (Alk) and type II (BMPR II) receptor. Receptors of both types are needed to form a functional complex for further signal transmission events through phosphorylation of Smad-1, -5 or -8. All BMPs use the same BMPR II, but they employ a varying repertoire of type I receptors. BMP-2 and -4 bind to Alk-3 and -6, whereas BMP-6 and -7 preferably bind to Alk-2 (ten Dijke et al., 1994b; Ebisawa et al., 1999) . Although the various BMPs make use of different type I receptors, all receptors activate the same downstream signalling pathway(s). This may explain the lack of synergy effects seen when we combined different BMPs, as shown in Figure 3 .
BMP-4 did not induce apoptosis or inhibit proliferation in INA-6 and RPMI-8226 cells, although these cell lines were sensitive to BMP-6 or -7. Accordingly, BMP-4 contrary to BMP-6 and -7 was unable to cause phosphorylation of Smad-1/5/8 in the same cell lines, suggesting that the lack of a functional receptor for BMP-4 could be the explanation for the unresponsiveness to this cytokine. In Figure 1 , we show that there is variability in the mRNA expression for type I receptors among the myeloma cell lines. The lack of Alk-3 and -6 expression on INA-6 and RPMI-8226 cells may explain why BMP-4 (and BMP-5) had no effect on these cells. The importance of Alk-3 and -6 for BMP-4-and -5-mediated signalling in myeloma cells was confirmed by experiments showing that Alk-3-Fc and -6-Fc were able to fully abolish BMP-4-induced growth repression.
It is not established which type I receptor BMP-5 uses, but Alk-3-Fc chimeric protein inhibited BMP-5-induced effects in cultured sympathetic neurons (Beck et al., 2001) , as it did to some extent in our experiments. With the exception of a minor effect on thymidine incorporation in RPMI-8226 cells, BMP-5 gave no response in cell lines without Alk-3 transcripts, thus indirectly supporting the notion that BMP-5 may signal by ligation to Alk-3. However, BMP-5-induced growth repression was only partially influenced by soluble Alk-3 and -6, suggesting that BMP-5 may also bind to other receptors besides Alk-3 or -6.
Two recent papers have focused on a more complicated form of BMP ligand-receptor interaction (Gilboa et al., 2000; Nohe et al., 2002) . Prior to ligand binding, heterocomplexes of BMPR II with BMPR I are the most prominent. Upon BMP-2 binding, a significant elevation in the amount of heteromeric BMP receptor complexes is seen, as well as an increase in homomeric BMPR I complexes (singly-expressed BMPR II cannot bind the ligand). In COS7 cells, BMP-2-induced homomeric complexes trigger an alternative pathway to the Smad pathway, the p38 MAPK pathway. This flexible oligomerization pattern allows a large variety and flexibility in the response to various ligands. The simultaneous activation of several downstream signalling pathways, or rather lack of activation of one of these pathways, could possibly explain why BMP-6 and -7 inhibited proliferation but had no effect on apoptosis on the ANBL-6 cell line. However, an alternative explanation may be a defect in the apoptotic pathway in these cells, as ANBL-6 cells seem relatively resistant to any apoptotic stimulation (our unpublished observations). Effects of the BMP antagonists noggin and follistatin. The cell line IH-1 was grown in media containing IL-6 with or without an excess of BMP antagonists and treated with BMP-4 (50 ng/ml), BMP-5 (300 ng/ml), BMP-6 (50 ng/ml), BMP-7 (50 ng/ml) or Activin A (50 ng/ml) for 72 h. DNA synthesis was measured by 3 H-thymidine incorporation. Noggin antagonized BMP-4-and -5-induced growth inhibition, but did not influence growth inhibition induced by BMP-6 or -7. Follistatin antagonized Activin A-induced effects fully and BMP-5-induced effects partially. Data shown are representative of three different experiments, and error bars represent þ 1 s.d. of triplicate measurements BMP-5, -6 and -7 inhibit myeloma cell growth T Baade Ro et al BMPs are tightly bound to the bone matrix, and the BMP level in the bone marrow compartment is difficult to measure. In normal bone, the total level of BMPs is reported to be approximately 2 mg/kg bone (Wozney, 1989) . Whether the BMP level is higher, equal or lower in the myeloma patient is not known. An insufficient concentration of BMPs may be one possible explanation as to why the myeloma cells survive in an environment with BMPs. Another explanation may be the presence of BMP antagonists in the bone marrow. Several BMP antagonists are described, including noggin (Zimmerman et al., 1996) and follistatin (Yamashita et al., 1995) . We detected minimal or no BMP antagonism by follistatin in our experiments. Noggin, however, antagonized BMP-4 effects completely and BMP-5 effects partially. Noggin is known to bind several BMPs in the extracellular space, among them BMP-4 and -7, thereby inhibiting ligand-receptor interactions. By binding to heparan sulfate proteoglycans, noggin is able to establish a BMP activity gradient reaching across several cell diameters (Paine-Saunders et al., 2002) , as heparan sulfate-bound noggin retains its biological activity and can bind BMPs. This is hypothesized to be a major post-translational mechanism to govern BMP activity, at least in the embryo. Interestingly, an elevated serum level of soluble heparan sulfate proteoglycan syndecan-1 is associated with an unfavorable prognosis for the myeloma patient (Seidel et al., 2000) . However, noggin only antagonized BMP-4 and -5 effects. Follistatin only antagonized BMP-5 and activin A effects. Thus, when present, BMP-6 and -7 should be able to inhibit proliferation of myeloma cells, despite the presence of noggin or follistatin.
Several clinical trials and animal experiments have been performed using bone morphogenetic proteins. BMP-7 implanted with a type I collagen carrier was a safe and effective treatment for tibial nonunions in patients (Friedlaender et al., 2001) . BMP-7 has also been given intravenously to rats, showing a neuroprotective effect of BMP-7 following induced cerebral ischemia as compared to control (Chang et al., 2003) . The antitumor effects of BMP-5, -6 or -7 have to our knowledge not been studied in clinical trials or animal experiments.
Bone morphogenetic proteins have a clear antitumor effect against myeloma cells in vitro. Bearing in mind the bone-inducing effect of BMPs, it is possible that therapeutic use of BMP to myeloma patients could have a beneficial impact on both myeloma bone disease and myeloma cell growth. Importantly, BMP-2-or -4-resistant myeloma cells may still be sensitive to BMP-6 or -7. Further studies on BMPs can result in new treatment for multiple myeloma.
Materials and methods
Cell lines and culture condition
We used the human myeloma cell lines ANBL-6 (kind gift from Dr D Jelinek, Mayo Clinic, Rochester, MN, USA), IH-1 (Brenne et al., 2002) , INA-6 (kind gift from Dr M Gramatzki, Erlangen, Germany), JJN-3 (Jackson et al., 1989) , OH-2 (Borset et al., 1994) , RPMI-8226 and U-266 (both from American Type Culture Collection, Rockville, MD, USA). Cells were grown in RPMI 1640 (Gibco, Paisley, UK) supplemented with L-glutamine (100 mg/ml) and gentamicin (20 mg/ml) (referred to as RPMI). ANBL-6 and INA-6 were cultured in RPMI supplemented with 10% heat inactivated fetal calf serum (FCS, HyClone, Logan, UT, USA), RPMI-8226 with 20% FCS. OH-2 and IH-1 cells were maintained in RPMI supplemented with heat inactivated 10% human serum (Blood Bank, Trondheim University Hospital, Trondheim, Norway). The IL-6-dependent cell lines ANBL-6, IH-1, INA-6 and OH-2 were cultured in media containing IL-6 (2 ng/ml). The media were replenished twice weekly. The cells were cultured at 371C in a humidified atmosphere containing 5% CO 2 . We washed the IL-6-dependent cell lines four times in Hanks' balanced salt solution (HBSS) (Gibco, Paisley, UK) to deplete the cells of cytokines before assays were performed.
Patients and isolation of myeloma cells
After obtaining approval from the regional ethics committee and informed consent from patients, we studied myeloma cells from nine patients admitted to the Section of Hematology, St Olav's Hospital, Trondheim. Patient characteristics are given in Table 1 . Myeloma cells from bone marrow aspirates were purified by immunomagnetic separation using Macs CD138 MicroBeads (Miltenyi Biotec, CA, USA). The purity of myeloma cells obtained by this method was X97%, as determined by cytospin preparations.
Reagents
Activin A, Alk-3-Fc, -6-Fc, BMP-2, -4, -5, -6, -7, follistatin and noggin were from R&D systems (Abingdon, UK). IL-6 was from Peprotech (London, UK). All cytokines used were recombinant human, except noggin (recombinant murine).
Proliferation assay
To measure DNA synthesis, cells were seeded in 96-well plastic culture plates (Corning Costar, Corning, NY, USA) at a density of 2 Â 10 4 cells/well in 200 ml of RPMI supplemented with 10% FCS (1% FCS for RPMI-8226) and cytokines, as indicated for each experiment. After 54 h, they were pulsed with 0.75 mCi methyl- 
Apoptosis assay
Cell viability and apoptosis were determined by flow cytometric analysis of annexin V-FITC binding and PI uptake (APOPTEST-FITC kit, Nexins Research, Hoeven, Netherlands), and performed as described (Hjertner et al., 2001) . The cells were incubated with cytokines as indicated, in RPMI containing 1% FCS (primary myeloma cells and RPMI-8226) or 10% FCS (all other cells).
mRNA analysis
Total RNA was isolated from 2 Â 10 6 cells using a RNeasy midi kit (Quiagen, Crawley, UK), and cDNA synthesis and reverse transcriptase (RT)-PCR were performed as described (Borset et al., 1996) . The following primers were used: actin 5 0 -ATCTGGCACCACACCTTCTACAATGA GCTGCG sense (s) and 5 0 -CGTCATACTCCTGCTTGCT BMP-5, -6 and -7 inhibit myeloma cell growth T Baade Ro et al GATCCACATCTGC antisense (as); Alk-2 5 0 -CTCCGAG TACCCCAGTGA (s) and 5 0 -CTGTGTTCCAGGGAAGGA (as); Alk-3 5 0 -CAGGAGCTCGATAGTATGCTTCATGGC (s) and 5 0 -AGGATCCTAAGAAATGAGCAAAACCAGC (as); Alk-6 5 0 -TGCGAAGTGCAGGAAAAT (s) and 5 0 -GGGATTCTCCAGGAGGAA (as). BMPR II 5 0 -CATTG GAGATCCCCAAGA (s) and 5 0 -ATATCGACCTCGGC CAAT (as). The primers were custom made by Eurogentec, Seraing, Belgium. All PCR products (except actin) were purified using Concert rapid PCR purification system (Life Technologies, Paisley, UK), sequenced using BigDye Terminator v2.0 Cycle Sequencing Kit (Applied Biosystems, CA, USA), and analysed using Blast (NCBI, MD, USA) to confirm sequence homology.
Western blotting
Cells were washed four times in HBSS and seeded in 0.5 ml RPMI-1640 with 0.1% BSA in 24-well plates (2 Â 10 6 cells/ well) with BMPs, as indicated. After 4 h incubation, the cells were pelleted and resuspended in 105 ml lysis buffer: 10 mM tris(hydroxymethyl)aminomethane-HCl (Tris-HCl), pH 7.4, 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM ethyleneglycoltetraacetic acid (EGTA), 1 mM NaF, 20 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton-X 100, 10% glycerol and a protease/ phosphatase inhibitor cocktail (Complete mini tablets from Roche, Basel, Switzerland). After 30 min on ice, the nuclei were pelleted by centrifugation at 12 000 g, 41C for 20 min. Supernatants were stored at À801C until further processing. Samples were mixed with LDS sample buffer (Invitrogen, Carlsbad, CA, USA) with 100 mM DTT, heated for 5 min at 981C and then separated on 10% NuPAGE Bis-tris gels (Invitrogen), followed by electrophoretic transfer to 0.45 mm nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 4% BSA in Tris-buffered saline with 0.05% Tween20 (TBS-T) and incubated with antibodies against phosphorylated Smad 1/5/8 (Chemicon, Temecula, CA, USA) overnight at 41C. Detection was performed with horseradish peroxidase-conjugated antibodies (DAKO Cytomation, Copenhagen, Denmark) and chemiluminescense (ECL, Amersham, Amersham, UK). The membranes were stripped at 601C for 30 min with gentle rotation in a buffer containing 62.5 mM Tris-HCl, pH 6.6, 2% SDS and 100 mM 2-mercaptoethanol, then washed in TBS-T, blocked with 5% nonfat, dried milk in TBS-T and probed with anti-Smad5 (Santa Cruz BT, Heidelberg, Germany) to verify equal loading.
Statistical analysis
Statistical significance was determined by using a two-tailed, unpaired Student's t-test. The minimal level of significance was P ¼ 0.05.
